Wockhardt, a company in the Pharmaceuticals industry, reported revenue of ₹969 crore and net profit of ₹73 crore for the September 2026 quarter.
Wockhardt (NSE: WOCKPHARMA) closed at ₹2,184.40 on 20 Nov 2026, up 64.8% over the past year. Its market capitalisation is ₹35,499 crore and it trades at 88.8 times earnings.
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.